2022 OMA临床实践声明：抗肥胖药物和研究药物.docx

下载文档

0
0
约25.09万字
约 66页
2024-05-11 发布于河南
举报
版权申诉
保障服务

2022 OMA临床实践声明：抗肥胖药物和研究药物.docx

1、本文档共66页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

ObesityPillars2(2022)100018

Contents

ContentslistsavailableatScienceDirect

ObesityPillars

journalhomepage:/obesity-pillars

Anti-ObesityMedicationsandInvestigationalAgents:AnObesityMedicineAssociation(OMA)ClinicalPracticeStatement(CPS)2022

HaroldE.Baysa,*,AngelaFitchb,SandraChristensenc,KarliBurridged,e,JustinTondtf

LouisvilleMetabolicandAtherosclerosisResearchCenter,UniversityofLouisvilleSchoolofMedicine,3288IllinoisAvenue,Louisville,KY,40213,USA

AssistantProfessorofMedicineHarvardMedicalSchool,Co-DirectorMassachusettsGeneralHospitalWeightCenter,Boston,MA,USA

IntegrativeMedicalWeightManagement,2611NE125thSt,Suite100B,Seattle,WA,98125,USA

EnaraHealth,16501106thCourt,OrlandPark,IL,60467,USA

GainingHealth,528PennsylvaniaAve#708,GlenEllyn,IL,60137,USA

DepartmentofFamilyandCommunityMedicine,EasternVirginiaMedicalSchool,P.O.Box1980,Norfolk,VA,23501,USA

ARTICLEINFO

ABSTRACT

Keywords:

Anti-obesitymedications

Investigationalagents

Obesity

Semaglutide

Tirzepatide

Background:This“Anti-ObesityMedicationsandInvestigationalAgents:AnObesityMedicineAssociationClinicalPracticeStatement2022”isintendedtoprovidecliniciansanoverviewofFoodandDrugAdministration(FDA)approvedanti-obesitymedicationsandinvestigationalanti-obesityagentsindevelopment.

Methods:Thescienti?cinformationforthisClinicalPracticeStatement(CPS)isbaseduponpublishedscienti?ccitations,clinicalperspectivesofOMAauthors,andpeerreviewbytheObesityMedicineAssociationleadership.

Results:ThisCPSdescribespharmacokineticprinciplesapplicabletothosewithobesity,anddiscussestheef?cacyandsafetyofanti-obesitymedications[e.g.,phentermine,semaglutide,liraglutide,phentermine/topiramate,naltrexone/bupropion,andorlistat,aswellasnon-systemicsuperabsorbentoralhydrogelparticles(whichiste